Also, failure to respond to imatinib was in some CML patients result of mutations arising in the BCR-ABL kinase domain (KD), leading to shortened survivals of CML patients with these mutations [8]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.